Regenerative Medicine Research Report 2024-2031: Approvals for New Regenerative Medicines and Increasing Applications of Regenerative Medicine in Newer Therapy Areas Driving the $37.27 Billion Market
19 déc. 2024 05h24 HE
|
Research and Markets
Dublin, Dec. 19, 2024 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis by Product Application End User - Global Forecast to 2031" report has been...
CAR-T Cell Therapy Market to Surpass USD 188.84 Billion by 2034 at 36.8% during 2025 to 2034 – Report by Polaris Market Research
19 déc. 2024 04h47 HE
|
Polaris Market Research & Consulting LLP
New York, USA, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Market Overview The market for CAR-T cell therapy is poised to exhibit a robust CAGR of 36.8% during 2025–2034. The CAR-T cell therapy market size...
Longeveron to Present at Biotech Showcase 2025
18 déc. 2024 09h10 HE
|
Longeveron
Longeveron Chief Executive Officer Wa’el Hashad will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025.
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
17 déc. 2024 08h00 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
invIOs to present progress across oncology pipeline during JP Morgan Week 2025
16 déc. 2024 09h00 HE
|
invIOs GmbH
VIENNA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in...
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
10 déc. 2024 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Ori Biotech and Fresenius Kabi Collaborate to Advance Modular, Scalable Manufacturing of Cell and Gene Therapies
10 déc. 2024 08h31 HE
|
Ori Biotech Ltd
Ori Biotech and Fresenius Kabi partner to integrate Ori’s IRO® Platform with Cue® and Lovo® systems, advancing scalable cell and gene therapy manufacturing
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
09 déc. 2024 21h00 HE
|
Lyell Immunopharma, Inc
Objective response rate (ORR) of 94% and a complete response (CR) rate of 71% demonstrated after IMPT-314 treatment in CAR T-naïve patients with large B-cell lymphoma who had received at least 2 prior...
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
09 déc. 2024 07h30 HE
|
Vor Biopharma
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to...
Smart Immune and CELLforCURE by SEQENS Partner to Industrialize SMART101 Clinical Batches Manufacturing
03 déc. 2024 00h00 HE
|
Smart Immune
PRESS RELEASE | Paris, France – December 3, 2024 Smart Immune, a clinical-stage biotechnology company, and CELLforCURE by SEQENS, a Contract Development and Manufacturing Organization (CDMO) for...